Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 from 8:45–9:25 AM ET. A live webcast and a replay will be available on the company’s Investor Relations website at www.cgen.com.
Positive
- None.
Negative
- None.
News Market Reaction – CGEN
In the Apr 9 session, CGEN gained 8.30%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.7% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Earnings results | Positive | +24.3% | Strong 2025 earnings, cash runway into 2029, CEO transition update. |
| Feb 19 | Investor conferences | Neutral | +5.3% | Announcement of management participation in two healthcare investor conferences. |
| Feb 17 | Earnings date set | Neutral | +1.8% | Scheduling of Q4 and full-year 2025 results release and conference call. |
| Feb 12 | Board appointment | Positive | -2.3% | Appointment of Dr. Michele Holcomb as independent director to strengthen board. |
| Dec 17 | Royalty monetization | Positive | +2.0% | Non-dilutive monetization of rilvegostomig royalties with AstraZeneca for cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CGEN has often reacted positively to fundamental and corporate updates, while governance and board changes have seen occasional negative divergence.
Over the last few months, CGEN reported strong 2025 results with $72.8M revenue and $35.3M net income, plus a cash runway into 2029. It highlighted royalty monetization with AstraZeneca for up to $90M and several governance and conference announcements. Earnings and monetization news on Dec 17, 2025 and Mar 2, 2026 saw positive price reactions, while a board appointment on Feb 12, 2026 coincided with a modest decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-25th-annual-needham-virtual-healthcare-conference-302738030.html
SOURCE Compugen Ltd.